Clinical trials: Skin Cancer Scalp
Actinic Keratosis
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on the balding scalp when applied topically once daily for 3 consecutive days as field treatment.
- Trial name
- NCT02547363
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 373 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on the balding scalp when applied topically once daily for 3 consecutive days as field treatment
- Trial name
- NCT02549352
- Testing
- LEO43204 gel, Vehicle gel
- Where
- Germany
- Volunteers
- 391 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
- Trial name
- NCT02838628
- Testing
- 50 mg of KX2-391 Ointment 1%
- Where
- 16 sites in United States
- Volunteers
- 168 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00915551
- Testing
- PEP005 (Ingenol Mebutate) gel, 0.015%, Vehicle Gel
- Where
- 21 sites in United States, Australia
- Volunteers
- 278 people
- Sponsor
- Peplin
Actinic Keratoses
PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK
Interventional open label prospective and multicentre study conducted in Germany in subjects with thin or non-hyperkeratotic and non-pigmented multiple AKs in one anatomical area on the face (e.g., forehead or cheek or chin)…
- Trial name
- SESAME 2 (NCT03511326)
- Testing
- Methyl Aminolaevulinate 16% Cream
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Galderma R&D
Actinic Keratosis
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
To determine the comparability of the safety and efficacy of Imiquimod Cream, 3.75% and Zyclara (imiquimod) Cream, 3.75% (the reference listed drug) in subjects with actinic keratosis (AK) of the face or balding scalp.
- Trial name
- NCT01686152
- Testing
- Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
- Where
- 23 sites in United States
- Volunteers
- 589 people
- Sponsor
- Teva Pharmaceuticals USA
Actinic Keratosis
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratosis when applied to broad areas on the face and scalp for 1, 2 and 3 hours.
- Trial name
- NCT01475955
- Testing
- Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation
- Where
- 13 sites in United States
- Volunteers
- 235 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Actinic Keratosis
A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase IIb study is designed to assess the safety and efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel when applied to an area of skin, containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00700063
- Testing
- PEP005 Topical Gel, Vehicle gel
- Where
- 28 sites in United States, Australia
- Volunteers
- 265 people
- Sponsor
- Peplin
Actinic Keratosis (AK)
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
The purpose of the study is to compare the risk of developing squamous skin cancer (SCC) or other types of cancer after treatment of AKs with ingenol mebutate gel or imiquimod cream.
- Trial name
- NCT01926496
- Testing
- Ingenol Mebutate Gel, 0.015%, Imiquimod Cream, 5%
- Where
- 46 sites in France, Germany and 1 more
- Volunteers
- 485 people
- Sponsor
- LEO Pharma
Actinic Keratosis
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00916006
- Testing
- PEP005 Gel, Vehicle gel
- Where
- 21 sites in United States, Australia
- Volunteers
- 269 people
- Sponsor
- Peplin
Actinic Keratosis
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
The purpose of this study was to compare the efficacy of Photodynamic Therapy (PDT) with methyl aminolevulinate (MAL) cream to PDT with vehicle cream, using the Light-emitting diode (LED) light source Aktilite CL128, in treatment…
- Trial name
- NCT00304239
- Testing
- Metvix-PDT, Vehicle-PDT
- Where
- 11 sites in United States, Germany
- Volunteers
- 131 people
- Sponsor
- Galderma R&D
Actinic Keratoses
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face…
- Trial name
- AK003 (NCT03285477)
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
- Trial name
- NCT02361216
- Testing
- Ingenol Mebutate, Vehicle
- Where
- United States
- Volunteers
- 729 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Actinic Keratosis (AK)
A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period
Once or twice daily 12 week treatment in patients with Actinic Keratosis randomized to treatment in one of four arms.
- Trial name
- NCT03116698
- Testing
- Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily
- Where
- 20 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Actinic Keratoses
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and…
- Trial name
- NCT04085367
- Testing
- MAL 16.8% cream, MAL Vehicle Cream
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Galderma R&D
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or…
- Trial name
- NCT01820260
- Testing
- Ingenol mebutate gel
- Where
- United States
- Volunteers
- 395 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.
- Trial name
- NCT01600014
- Testing
- Ingenol mebutate gel, 0.015%, Vehicle gel
- Where
- 13 sites in Australia, Canada and 3 more
- Volunteers
- 463 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for two consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to…
- Trial name
- NCT02100813
- Testing
- LEO 43204
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- LEO Pharma
Actinic Keratosis
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
The purpose of this trial is to compare the rate of complete clearance of actinic keratosis (AK) using sequential cryotherapy and field treatment with PEP005 Gel compared to cryotherapy alone.
- Trial name
- NCT01541553
- Testing
- Cryotherapy, Vehicle, Ingenol metabute
- Where
- 35 sites in United States
- Volunteers
- 367 people
- Sponsor
- LEO Pharma
Keratosis, Actinic
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).
- Trial name
- PROAK (NCT05260073)
- Testing
- Tirbanibulin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Almirall, S.A.